•
Dec 31, 2023

Rockwell Medical Q4 2023 Earnings Report

Rockwell Medical achieved profitability on an Adjusted EBITDA basis and record net sales, gross profit, and gross margin for the full year.

Key Takeaways

Rockwell Medical reported achieving profitability on an adjusted EBITDA basis in Q4 2023, alongside record net sales, gross profit, and gross margin for the full year 2023. The company has focused on improving financial health, securing multi-year agreements, expanding geographically, and improving manufacturing efficiencies.

Achieved profitability on an adjusted EBITDA basis in Q4 2023.

Generated the highest revenue and gross profit to-date for the company in 2023.

Completed two acquisitions and renegotiated customer agreements.

Expanded geographic footprint both domestically and internationally.

Total Revenue
$22.1M
Previous year: $19.3M
+14.4%
EPS
$0.02
Previous year: -$0.2
-110.0%
Gross Profit
$2.87M
Previous year: $2.34M
+22.6%
Cash and Equivalents
$10.9M
Previous year: $21.5M
-49.1%
Total Assets
$52.2M
Previous year: $46.6M
+11.9%

Rockwell Medical

Rockwell Medical

Forward Guidance

Rockwell Medical projects net sales to grow in the mid-to-high single digits in 2025 and beyond. Rockwell Medical projects gross margin in 2025 to be approximately 20% and reaching above 25% in 2026 and beyond.